Kantar Health Blog

  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO GU --- Surgical resection is the primary treatment for patients with early-stage renal cell carcinoma (RCC) and can potentially be curative in up to 70% of cases. In many solid tumors, patients at high risk of recurrence are often treated with adjuvant (postsurgical) systemic therapy, with the idea being to eradicate any microscopic residual disease and thus decrease the likelihood of developing a local or metastatic recurrence.
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO GI --- Patients with metastatic colorectal cancer (mCRC) are typically treated at some point with at least one angiogenesis inhibitor. According to Kantar Health’s CancerMPact® Treatment Architecture U.S. data, Avastin® (bevacizumab, Genentech/Roche) is offered to approximately one-half of KRAS wild-type chemotherapy-naïve patients and three-quarters of KRAS mutated chemotherapy-naïve patients in the first-line setting. In the second- or third-line setting, patients might be treated with Avastin, Zaltrap® (ziv-aflibercept, Sanofi) or Stivarga® (regorafenib, Bayer/Onyx).
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASCO GI --- Designated as a “breakthrough therapy” by the FDA for both advanced and unresectable malignant melanoma and advanced non-small cell lung cancer (NSCLC), and approved by the U.S. Food and Drug Administration (FDA) in September 2014 for advanced pretreated metastatic melanoma, the immune checkpoint inhibitor Keytruda® (pembrolizumab, Merck) has also shown promise for several other indications including (but not limited to) head and neck cancer, Hodgkin’s lymphoma and triple-negative breast cancer (TNBC).
    Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne Continue Reading > | Go comment! | Share
  • Stephanie Hawthorne
    Oncology Conference Insight: ASH 2014 --- Immune checkpoints in the Programmed Death -1 (PD-1) pathway have critical roles in balancing the co-stimulatory and co-inhibitory signals that regulate human self-tolerance and control the amplitude and duration of T‑cell responses. PD-1 is a key immune checkpoint receptor expressed on activated T-cells. Binding of PD-1 to its ligand (PD-L1) results in suppression of the immune response and tumor cells can manipulate this critical pathway to elude attack by tumor-infiltrating T-cells.
    Continue Reading > | Go comment! | Share